{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:52Z","timestamp":1790743792436,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40262-019-00816-7","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T01:02:22Z","timestamp":1566781342000},"page":"37-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-0439","authenticated-orcid":false,"given":"Antoine","family":"Petitcollin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Bensalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bellissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"issue":"2","key":"816_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","volume":"11","author":"H Kaplon","year":"2019","unstructured":"Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219\u201338.","journal-title":"MAbs."},{"issue":"10","key":"816_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"816_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/19420862.2015.1075109","volume":"7","author":"A Datta-Mannan","year":"2015","unstructured":"Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs. 2015;7(6):1084\u201393.","journal-title":"MAbs."},{"issue":"7","key":"816_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/19420862.2016.1208330","volume":"8","author":"RL Kelly","year":"2016","unstructured":"Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, et al. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs. 2016;8(7):1269\u201375.","journal-title":"MAbs."},{"issue":"2","key":"816_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58(2):169\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"816_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52(12):1918\u201326.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"816_CR7","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovic S, Mrhar A, Jezersek Novakovic B. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83(8):1782\u201390.","journal-title":"Br J Clin Pharmacol"},{"key":"816_CR8","doi-asserted-by":"crossref","unstructured":"Li j, Levi M, Charoin J-E, Frey N, Kheoh T, Ren S, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-hodgkin\u2019s lymphoma (NHL) patients. Blood. 2007;110(11):2371.","DOI":"10.1182\/blood.V110.11.2371.2371"},{"key":"816_CR9","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1038\/psp.2014.42","volume":"3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacometr Syst Pharmacol. 2014;3:e144.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"1","key":"816_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometr Syst Pharmacol. 2017;6(1):58\u201366.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"5","key":"816_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403\u201314.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"816_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"816_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cpt.577","volume":"101","author":"XS Xu","year":"2017","unstructured":"Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"816_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2125.2007.02967.x","volume":"65","author":"D Ternant","year":"2008","unstructured":"Ternant D, Buchler M, Beneton M, Alvan G, Ohresser M, Touchard G, et al. Interindividual variability in the concentration-effect relationship of antilymphocyte globulins: a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol. 2008;65(1):60\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"816_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40262-018-0694-x","volume":"58","author":"JC Masters","year":"2019","unstructured":"Masters JC, Barry E, Knight B. Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Pharmacokinet. 2019;58(2):271\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"816_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-018-0699-5","volume":"58","author":"J Hibma","year":"2019","unstructured":"Hibma J, Knight B. Population pharmacokinetic modeling of gemtuzumab ozogamicin in adult patients with acute myeloid leukemia. Clin Pharmacokinet. 2019;58(3):335\u201347.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"816_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-017-0535-3","volume":"56","author":"N Vande Casteele","year":"2017","unstructured":"Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, et al. Accounting for pharmacokinetic variability of certolizumab pegol in patients with Crohn\u2019s disease. Clin Pharmacokinet. 2017;56(12):1513\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"816_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, et al. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol. 2017;83(8):1773\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"816_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/cpt.1429","volume":"106","author":"Antoine Petitcollin","year":"2019","unstructured":"Petitcollin A, Brochard C, Siproudhis L, Tron C, Verdier MC, Lemaitre F, et al. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. Clin Pharmacol Ther. Epub 12 Mar 2019. https:\/\/doi.org\/10.1002\/cpt.1429.","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"816_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometr Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"3","key":"816_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","volume":"24","author":"C Krieckaert","year":"2012","unstructured":"Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306\u201311.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"816_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1208\/s12248-016-0018-8","volume":"19","author":"S Bian","year":"2017","unstructured":"Bian S, Ferrante M, Gils A. Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab. AAPS J. 2017;19(2):468\u201374.","journal-title":"AAPS J."},{"key":"816_CR23","doi-asserted-by":"crossref","unstructured":"Bendtzen K. Immunogenicity of anti-TNF-alpha biotherapies: II. clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6:109.","DOI":"10.3389\/fimmu.2015.00109"},{"issue":"8","key":"816_CR24","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.491","volume":"55","author":"JR Wade","year":"2015","unstructured":"Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn\u2019s disease. J Clin Pharmacol. 2015;55(8):866\u201374.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"816_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","volume":"30","author":"D Ternant","year":"2008","unstructured":"Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30(4):523\u20139.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"816_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/FTD.0000000000000494","volume":"40","author":"SE Berends","year":"2018","unstructured":"Berends SE, Strik AS, Van Selm JC, Lowenberg M, Ponsioen CY, D\u2019Haens GR, et al. Explaining interpatient variability in adalimumab pharmacokinetics in patients with Crohn\u2019s disease. Ther Drug Monit. 2018;40(2):202\u201311.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"816_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1208\/s12248-014-9623-6","volume":"16","author":"S Bihorel","year":"2014","unstructured":"Bihorel S, Fiedler-Kelly J, Ludwig E, Sloan-Lancaster J, Raddad E. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J. 2014;16(5):1009\u201317.","journal-title":"AAPS J."},{"issue":"5","key":"816_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/apt.13299","volume":"42","author":"DJ Buurman","year":"2015","unstructured":"Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42(5):529\u201339.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"816_CR29","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247\u201359.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"816_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946\u201364.","journal-title":"Clin Ther"},{"issue":"12","key":"816_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211\u201328.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"816_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00280-016-2984-z","volume":"77","author":"A Gupta","year":"2016","unstructured":"Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA. Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. Cancer Chemother Pharmacol. 2016;77(4):733\u201343.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"816_CR33","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/jcph.894","volume":"57","author":"KK Muralidharan","year":"2017","unstructured":"Muralidharan KK, Kuesters G, Plavina T, Subramanyam M, Mikol DD, Gopal S, et al. Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol. 2017;57(8):1017\u201330.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"816_CR34","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1128\/AAC.06446-11","volume":"56","author":"GJ Robbie","year":"2012","unstructured":"Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927\u201336.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"816_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","volume":"21","author":"S Sharma","year":"2015","unstructured":"Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21(4):783\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"816_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305\u201312.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"816_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00228-015-1892-1","volume":"71","author":"D Ternant","year":"2015","unstructured":"Ternant D, Karmiris K, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, et al. Pharmacokinetics of adalimumab in Crohn\u2019s disease. Eur J Clin Pharmacol. 2015;71(9):1155\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"816_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/psp4.12160","volume":"6","author":"B Wang","year":"2017","unstructured":"Wang B, Yan L, Yao Z, Roskos LK. Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma. CPT Pharmacometr Syst Pharmacol. 2017;6(4):249\u201357.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"9","key":"816_CR39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/0091270009339192","volume":"49","author":"Z Xu","year":"2009","unstructured":"Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056\u201370.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"816_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5414\/CPP48596","volume":"48","author":"ZH Xu","year":"2010","unstructured":"Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther. 2010;48(9):596\u2013607.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"816_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162\u201375.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"816_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5414\/CPP48830","volume":"48","author":"YW Zhu","year":"2010","unstructured":"Zhu YW, Mendelsohn A, Pendley C, Davis HM, Zhou H. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int J Clin Pharmacol Ther. 2010;48(12):830\u201346.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"816_CR43","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/annrheumdis-2012-202407","volume":"72","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72(10):1680\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"816_CR44","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","volume":"63","author":"B Ungar","year":"2014","unstructured":"Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63(8):1258\u201364.","journal-title":"Gut"},{"issue":"3","key":"816_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10928-016-9469-x","volume":"43","author":"L Gibiansky","year":"2016","unstructured":"Gibiansky L, Passey C, Roy A, Bello A, Gupta M. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed\/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243\u201357.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"816_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","volume":"56","author":"A Nader","year":"2017","unstructured":"Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56(9):1091\u2013102.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"816_CR47","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-016-0366-7","volume":"55","author":"L Diao","year":"2016","unstructured":"Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers and subjects with multiple sclerosis: analysis of phase I\u2013III clinical trials. Clin Pharmacokinet. 2016;55(8):943\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"816_CR48","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1007\/s11095-011-0481-y","volume":"28","author":"T Kakkar","year":"2011","unstructured":"Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28(10):2530\u201342.","journal-title":"Pharm Res"},{"key":"816_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pupt.2017.08.010","volume":"46","author":"R Zhu","year":"2017","unstructured":"Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, et al. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. Pulm Pharmacol Ther. 2017;46:88\u201398.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"816_CR50","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"816_CR51","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/ibd\/izy129","volume":"24","author":"A Petitcollin","year":"2018","unstructured":"Petitcollin A, Leuret O, Tron C, Lemaitre F, Verdier MC, Paintaud G, et al. Modeling immunization to infliximab in children with crohn\u2019s disease using population pharmacokinetics: a pilot study. Inflamm Bowel Dis. 2018;24(8):1745\u201354.","journal-title":"Inflamm Bowel Dis"},{"key":"816_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000478077","volume":"53","author":"S Garces","year":"2018","unstructured":"Garces S, Demengeot J. The immunogenicity of biologic therapies. Curr Probl Dermatol. 2018;53:37\u201348.","journal-title":"Curr Probl Dermatol"},{"issue":"2","key":"816_CR53","doi-asserted-by":"publisher","first-page":"251-258.e2","DOI":"10.1016\/j.cgh.2015.10.029","volume":"14","author":"Johannan F. Brandse","year":"2016","unstructured":"Brandse JF, Mathot RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol. 2016;14(2):251-8 e1-2.","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4","key":"816_CR54","doi-asserted-by":"publisher","first-page":"e0175207","DOI":"10.1371\/journal.pone.0175207","volume":"12","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207.","journal-title":"PLoS One"},{"issue":"10","key":"816_CR55","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EM van Brummelen","year":"2016","unstructured":"van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 2016;21(10):1260\u20138.","journal-title":"Oncologist"},{"key":"816_CR56","doi-asserted-by":"publisher","first-page":"604872","DOI":"10.1155\/2015\/604872","volume":"2015","author":"I Arstikyte","year":"2015","unstructured":"Arstikyte I, Kapleryte G, Butrimiene I, Venalis A. Influence of immunogenicity on the efficacy of long-term treatment with TNF alpha blockers in rheumatoid arthritis and spondyloarthritis patients. Biomed Res Int. 2015;2015:604872.","journal-title":"Biomed Res Int"},{"issue":"8","key":"816_CR57","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50(8):1445\u201352.","journal-title":"Rheumatology"},{"issue":"7","key":"816_CR58","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-019-00738-4","volume":"58","author":"L Yan","year":"2019","unstructured":"Yan L, Wang B, Chia YL, Roskos LK. Population pharmacokinetic modeling of benralizumab in adult and adolescent patients with asthma. Clin Pharmacokinet. 2019;58(7):943\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"816_CR59","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/0091270008316886","volume":"48","author":"Z Xu","year":"2008","unstructured":"Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008;48(6):681\u201395.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-019-00816-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T03:57:54Z","timestamp":1650081474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-019-00816-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00816-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"26 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Antoine Petitcollin, Amina Bensalem, Marie-Cl\u00e9mence Verdier, Camille Tron, Florian Lemaitre, Gilles Paintaud, Eric Bellissant, and David Ternant declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This work was not supported by any funding source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}